Study seeking to isolate antibodies against rabies virus

April 30, 2018, Vanderbilt University

Few people die from rabid animal bites in the United States thanks to the near-universal availability of human rabies immune globulin and rabies vaccine, which are given as separate shots as soon as possible after exposure to the rabies virus.

That isn't the case in resource-poor countries. Around the world, an estimated 60,000 people die from rabies every year because they can't afford or don't have prompt access to the necessary combined treatment.

Immune globulin (the antibody part of the blood) is obtained from people who have previously been vaccinated against rabies. Rabies-vaccinated donors are few and far between in many countries, however, and as a result immune globulin is often in short supply.

To meet the challenge, James Crowe Jr., MD, and his colleagues in the Vanderbilt Vaccine Center have begun an effort to isolate against the . Monoclonal antibodies can be mass-produced and manufactured as biological drugs.

If the research is successful, anti-rabies could be developed as the standard treatment for animal bites throughout the world, Crowe said. That would solve the chronic shortage of human and save many lives.

Because identifying the initial antibodies as candidates for development is a small project, Crowe's lab is pursuing a "crowdfunding" approach to raising the $18,000 it needs to complete the research by the end of 2018 rather than apply for government or foundation support.

"Crowdfunding allows people who are interested in this work to participate and support it directly," said Crowe, the Ann Scott Carell Professor in the Departments of Pediatrics and Pathology, Microbiology and Immunology in the Vanderbilt University School of Medicine.

"The funding mechanism allows us to update the donors directly in real-time on our progress," Crowe added. Donors also can submit questions or comments for the researchers.

Explore further: Clinical trial for rabies monoclonal antibody

More information: For more information, see … t-for-rabies-disease

Related Stories

Clinical trial for rabies monoclonal antibody

August 7, 2012
A pivotal clinical trial for an anti-rabies human monoclonal antibody (RMAb) being developed through a collaborative partnership between MassBiologics of the University of Massachusetts Medical School and the Serum Institute ...

Researchers identify potential antibody treatment for H7 avian flu

March 9, 2016
Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.

6-year-old Florida boy dies of rabies contracted from a bat

January 15, 2018
A 6-year-old Florida boy has died from rabies he contracted after being scratched by an infected bat.

Recommended for you

Urbanisation and air travel leading to growing risk of pandemic

December 13, 2018
Increased arrivals by air and urbanisation are the two main factors leading to a growing vulnerability to pandemics in our cities, a University of Sydney research team has found.

Faecal transplants, 'robotic guts' and the fight against deadly gut bugs

December 13, 2018
A simple compound found in our gut could help to stop dangerous bacteria behind severe, and sometimes fatal, hospital infections.

Taking the virus out of a mosquito's bite

December 12, 2018
They approach with the telltale sign—a high-pitched whine. It's a warning that you are a mosquito's next meal. But that mosquito might carry a virus, and now the virus is in you. Now, with the help of state-of-the-art technology, ...

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Effect of oral alfacalcidol on clinical outcomes in patients without secondary hyperparathyroidism

December 11, 2018
Treatment with active vitamin D did not decrease cardiovascular events in kidney patients undergoing hemodialysis, according to a research group in Japan. They have reported their research results in the December 11 issue ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.